EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of Mepolizumab on Airway Remodeling and Inflammation in Severe Eosinophilic Asthma

Camille Taillé, Fatima Hamidi, Nicolas Heddebaut, Nicolas Poté, Pierre Le Guen, Mathilde Le Brun, Carine Roy, Axelle Dupont, Séverine Létuvé

CHEST · 2026-04 · 169 (4) · 890-901

DOI: 10.1016/j.chest.2025.10.047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CHEST, 2026-04. Verfasst von Camille Taillé und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pneumology, Allergology and Transplantation Department, AP-HP, Hôpital Bichat, Paris, France; Inserm, Unit 1149, Université Paris Cité, Paris, France…. Hauptthemen laut MEDLINE: Asthma, Airway Remodeling, Antibodies, Monoclonal, Humanized, Pulmonary Eosinophilia. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: IL-5 is a key mediator of severe eosinophilic asthma (SEA) and also may contribute to airway remodeling. RESEARCH QUESTION: Can mepolizumab, an anti-IL-5 antibody, modify airway remodelling in adult patients with SEA? STUDY DESIGN AND METHODS: Thirty-seven patients who were eligible for mepolizumab were included prospectively. Mepolizumab 100 mg was administered subcutaneously every 4 weeks for 12 months. Bronchial biopsies and bronchoalveolar lavage (BAL) were performed at baseline, 6 months, and 12 months. Clinical and functional outcomes, airway remodeling, and inflammatory markers were assessed at each time point. RESULTS: At 12 months, mepolizumab was shown to improve asthma control and FVC before bronchodilation and reduce the number of exacerbations, oral corticosteroid courses, and hospitalizations. These clinical and functional improvements were associated with a reduction in reticular basement membrane thickness (P < 0.0001), airway smooth muscle (ASM) mass (P = .0066), and proliferating cell nuclear antigen-positive ASM cells (P < .0001) in the bronchial mucosa at both 6 and 12 months. BAL fluid showed reduced levels of tenascin-C at 6 and 12 months and of fibulin-1 at 12 months. Blood eosinophil counts decreased significantly (P < .0001), and eosinophils were almost completely depleted in BAL fluid (P = .023) at 12 months. Submucosal eosinophilia was reduced to a lesser extent (P = .063). INTERPRETATION: In addition to its antiinflammatory effects, mepolizumab also may attenuate structural airway changes in SEA, which could contribute to its clinical benefits. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT03797404; URL: www. CLINICALTRIALS: gov.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaAirway RemodelingAntibodies, Monoclonal, HumanizedPulmonary EosinophiliaHumansFemaleMaleAdultProspective StudiesMiddle AgedBronchoalveolar Lavage FluidTreatment OutcomeInterleukin-5BronchiEosinophilsInflammationSeverity of Illness Index

Stichwörter der Autor:innen

IL-5airway remodelingbiologiceosinophilreticular basement membrane

Substanzen

mepolizumabAntibodies, Monoclonal, HumanizedInterleukin-5

Autor:innen und Institutionen

  • Pneumology, Allergology and Transplantation Department, AP-HP, Hôpital Bichat, Paris, France; Inserm, Unit 1149, Université Paris Cité, Paris, France; Clinical Research Initiative in Severe Asthma: A Lever for Innovatio…
  • Inserm, Unit 1149, Université Paris Cité, Paris, France.
  • Department of Pathology, AP-HP, Hôpital Bichat, Paris, France.
  • Pneumology, Allergology and Transplantation Department, AP-HP, Hôpital Bichat, Paris, France.
  • Department of Statistics and Clinical Research, AP-HP, Hôpital Bichat, Paris, France.

Förderung

  • GSK

Zitieren

APA

Taillé, C., Hamidi, F., Heddebaut, N., Poté, N., Le Guen, P., Le Brun, M., Roy, C., Dupont, A., & Létuvé, S. (2026). Impact of Mepolizumab on Airway Remodeling and Inflammation in Severe Eosinophilic Asthma. CHEST, 169(4), 890-901. https://doi.org/10.1016/j.chest.2025.10.047

Vancouver

Taillé C, Hamidi F, Heddebaut N, Poté N, Le Guen P, Le Brun M, et al. Impact of Mepolizumab on Airway Remodeling and Inflammation in Severe Eosinophilic Asthma. CHEST. 2026;169(4):890-901. doi:10.1016/j.chest.2025.10.047

BibTeX
@article{Taill2026,
  author = {Taillé, Camille and Hamidi, Fatima and Heddebaut, Nicolas and Poté, Nicolas and Le Guen, Pierre and Le Brun, Mathilde and Roy, Carine and Dupont, Axelle and Létuvé, Séverine},
  title = {Impact of Mepolizumab on Airway Remodeling and Inflammation in Severe Eosinophilic Asthma},
  journal = {CHEST},
  year = {2026},
  volume = {169},
  number = {4},
  pages = {890--901},
  doi = {10.1016/j.chest.2025.10.047}
}
Kostenlos starten →